Immuno-Oncology | Specialty

Dr. Ferris on Immunotherapy in Locally Advanced Head and Neck Cancer

June 19th 2017

Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses immunotherapy in patients with locally advanced head and neck cancer.

Petrylak Discusses Progress With Pembrolizumab in Urothelial Carcinoma

June 19th 2017

Daniel P. Petrylak, MD, discusses the KEYNOTE-045 results and the next steps with pembrolizumab (Keytruda) in urothelial carcinoma.

Pembrolizumab Plus Rituximab Promising in Follicular Lymphoma

June 17th 2017

Combining pembrolizumab with rituximab induced a high response rate in patients with relapsed follicular lymphoma.

Dr. Atkins Discusses the IMmotion150 Trial in RCC

June 16th 2017

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses the IMmotion150 trial in renal cell carcinoma.

Dr. Chowdhury on Pembrolizumab Plus Pazopanib in RCC

June 16th 2017

Simon Chowdhury, MD, consultant medical oncologist specializing in urological cancer, Sarah Cannon Research Institute, United Kingdom, discusses the combination of pembrolizumab (Keytruda) and pazopanib (Votrient) in patients with renal cell carcinoma (RCC).

Efficacy of Pembrolizumab in Multiple Subtypes of Sarcoma

June 16th 2017

Lisa H. Butterfield, PhD, professor of medicine, surgery, and immunology, director, University of Pittsburgh Immunologic Monitoring and Cellular Products Laboratory, University of Pittsburgh, president of the Society for Immunotherapy of Cancer, discusses a clinical trial exploring the PD-1 inhibitor pembrolizumab (Keytruda) in multiple subtypes of sarcoma.

Dr. Berinstein on Combination Treatments for High-Risk and Recurrent Follicular Lymphoma

June 16th 2017

Neil L. Berinstein, MD, professor, University of Toronto, Sunnybrook Health Sciences Centre, discusses combination treatments for patients with high-risk or recurrent follicular lymphoma.

Expert Discusses Latest Nivolumab Data in Hodgkin Lymphoma

June 15th 2017

High levels of response were observed with nivolumab (Opdivo), regardless of previous treatment with brentuximab vedotin (Adcetris), in patients with relapsed/refractory Hodgkin lymphoma after autologous stem-cell transplant.

Dr. Nastoupil on Pembrolizumab Plus Rituximab in Relapsed Follicular Lymphoma

June 15th 2017

Loretta J. Nastoupil, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses high response rates with prembrolizumab (Keytruda) in combination with rituximab (Rituxan) in patients with relapsed follicular lymphoma.

Dr. Machiels on Ongoing Trial of Pembrolizumab Plus Chemoradiation in HNSCC

June 14th 2017

Jean-Pascal Machiels, MD, head of the Department of Medical Oncology, Cliniques Universitaires Sain-Luc, discusses an ongoing clinical trial of pembrolizumab (Keytruda) combined with chemoradiation in patients with locally advanced head and neck squamous cell carcinoma (HNSCC).

Dr. Rini on Pembrolizumab Plus Axitinib in RCC

June 14th 2017

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses a phase I study of pembrolizumab (Keytruda) plus axitinib (Inlyta) in patients with renal cell carcinoma (RCC).

Dr. Lee on the Impact of Immunotherapy in Head and Neck Cancer

June 14th 2017

Nancy Y. Lee, MD, vice chair, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, discusses the impact of immunotherapy in head and neck cancer.

Dr. Fuchs Discusses Immunotherapy in Gastric Cancer

June 13th 2017

Charles S. Fuchs, MD, MPH, director, Yale Cancer Center, physician-in-chief, Smilow Cancer Hospital, 2017 Giant of Cancer Care in Gastrointestinal Cancer, discusses immunotherapy in gastric cancer.

Merck Pauses Enrollment in 2 Pembrolizumab Myeloma Trials

June 13th 2017

Merck announced that it is postponing enrollment in the phase III KEYNOTE-183 and KEYNOTE-185 trials because of deaths in patients with multiple myeloma assigned to pembrolizumab (Keytruda), the company's blockbuster anti-PD-1 therapy.

Dr. Apolo on Immunotherapy Combinations With Cabozantinib in Genitourinary Tumors

June 13th 2017

Andrea Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses immunotherapy combinations with cabozantinib (Cometriq) in genitourinary tumors.

Dr. Petrylak on the KEYNOTE-045 Trial for Urothelial Carcinoma

June 9th 2017

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, 2017 Giant of Cancer Care in Genitourinary Cancer, discusses the KEYNOTE-045 trial investigating pembrolizumab (Keytruda) versus physician’s choice of chemotherapy for patients with urothelial carcinoma.

Dr. Choueiri on Avelumab Plus Axitinib in mRCC

June 8th 2017

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses phase I results of axitinib (Inlyta) plus avelumab (Bavencio) for the treatment of patients with metastatic renal cell carcinoma (RCC).

Avelumab/Axitinib Combo Shows Promise in Frontline RCC

June 7th 2017

Combining the PD-L1 inhibitor avelumab (Bavencio) with the VEGF inhibitor axitinib (Inlyta) as a frontline regimen induced a response rate of 58.2% in patients with advanced renal cell carcinoma, according to findings from the phase Ib JAVELIN Renal 100 trial presented at the 2017 ASCO Annual Meeting.

Pembrolizumab/ Epacadostat Combo Active in Urothelial Carcinoma

June 6th 2017

Combining the PD-1 inhibitor pembrolizumab with the IDO1 inhibitor epacadostat led to an overall response rate of 35% in patients with advanced urothelial carcinoma.

Epacadostat/ Nivolumab Shows Promising Efficacy for Melanoma, Head and Neck Cancer

June 6th 2017

The combination of the IDO inhibitor epacadostat and nivolumab demonstrated promising signs of activity for patients with squamous cell carcinoma of the head and neck and those with melanoma.